Compare Enveric Biosciences Inc (ENVB) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs PepsiCo, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while PepsiCo, Inc. trades at $138.12 (market cap $187.99B). The key difference: PepsiCo, Inc. is far larger — about 30321× Enveric Biosciences Inc's market cap, and PepsiCo, Inc. pays a 4.3% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PEP | |
|---|---|---|
Market Cap | $6.20M | $187.99B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $170.44 |
52-Week Low | $1.27 | $134.95 |
Enterprise Value | $1.30M | $230.48B |
Dividend Yield | — | 4.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93 billion in 2025, with a net income margin of 10.78%, and has beaten EPS estimates in recent quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts anticipate Q1 2026 results.
The outlook is mixed: strong profitability and dividend yield near 4% support value, but price sensitivity and competitive pressures pose risks. Analyst consensus is a 'Hold' with a $158.79 price target, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
